Dr.EndoEP said:Compounding pharmacy response time test for compounded supply: I email customer service at odd hours to test responsiveness.
503A vs 503B compounding pharmacies for compounded supply — this distinction matters enormously:
| Feature | 503A | 503B |
|---|---|---|
| Regulation | State Board of Pharmacy | FDA-registered |
| Prescription | Required (patient-specific) | Can compound without patient Rx |
| Testing | Varies by state | cGMP required |
| Scale | Small batches | Larger production |
| Quality consistency | Variable | Generally higher |
I strongly recommend 503B facilities. The FDA oversight and cGMP requirements mean more consistent product quality.
Dr.RheumBOS said:Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured…
Thank you for spelling out the reasoning rather than just the conclusion. Taking it to my next appointment.
Dr.EndoEP said:Compounding pharmacy response time test for compounded supply: I email customer service at odd hours to test responsiveness.
I have been on both brand and compounded, and in the context of compounded supply, my experience has been equivalent with both. The key is finding a reliable 503B pharmacy with independent testing.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardsricardo_MIA said:Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…
Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.
Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide partially resolved shortage, tirzepatide still in shortage. This directly impacts compounding availability.
Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Carry on.